¸¶¾à¼º ÁøÅëÁ¦ »ç¿ë°ú ºÎ½Å±â´ÉºÎÀü
Opioids Use and Adrenal Insufficiency

Journal of Hospice and Palliative Care 2014³â 17±Ç 3È£ p.113 ~ p.121

Á¤ÁöÈÆ(Jung Ji-Hoon) - °í·Á´ëÇб³ ±¸·Îº´¿ø °¡Á¤ÀÇÇаú
ÃÖÀ±¼±(Choi Youn-Seon) - °í·Á´ëÇб³ ±¸·Îº´¿ø °¡Á¤ÀÇÇаú
±èÁ¤Àº(Kim Jung-Eun) - °í·Á´ëÇб³ ±¸·Îº´¿ø °¡Á¤ÀÇÇаú
±èÀÌ¿¬(Kim E-Yeon) - °í·Á´ëÇб³ ±¸·Îº´¿ø °¡Á¤ÀÇÇаú

Abstract

Ä¡·á ºÒ°¡´ÉÇÑ ¾ÏȯÀÚµéÀº Àü½ÅÀû ¼è¾à À̿ܿ¡ ÇÇ·Î¿Í ¿¡³ÊÁö »ó½Ç, ¹«·Â°¨, ½Ä¿åºÎÁø ¹× ÅëÁõ µîÀÌ ÁÖ¿ä Áõ»óÀ¸·Î ¾Ë·ÁÁ® ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Áõ»óµéÀº ºÎ½Å±â´ÉºÎÀüÀ¸·Î ÀÎÇÑ Áõ»óµé°ú ¸Å¿ì À¯»çÇÑ ¾ç»óÀ» º¸ÀδÙ. ºÎ½Å±â´ÉºÎÀüÀ¸·Î ÀÎÇÑ Áõ»óµéÀº °¡º­¿î Áõ»óºÎÅÍ »ý¸íÀ» À§ÇùÇÏ´Â Áõ»ó±îÁö ´Ù¾çÇÏ°Ô ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ºÎ½Å±â´ÉºÎÀüÀº ´Ù¾çÇÑ ¿øÀο¡ ÀÇÇØ ³ªÅ¸³­´Ù. ¿ÏÈ­ÀǷẴµ¿¿¡ ÀÔ¿ø ÁßÀÎ ¸»±â¾ÏȯÀÚµé Áß Áߵ ÀÌ»óÀÇ ÅëÁõÀ» È£¼ÒÇϴ ȯÀÚµéÀº ¸¶¾à¼º ÁøÅëÁ¦¸¦ »ç¿ëÇÏ¿© ÅëÁõ Á¶ÀýÀ» ¹Þ°í Àִµ¥, ÀÌ·¯ÇÑ ¸¶¾à¼º ÁøÅëÁ¦ÀÇ »ç¿ëÀº ºÎ½Å±â´É¿¡ ¿µÇâÀ» ÁÖ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. µ¿¹° ¹× ºñ¾Ï¼º ÅëÁõÀ» È£¼ÒÇϴ ȯÀÚ ´ë»óÀ¸·Î ¿©·¯ ¿¬±¸µéÀÌ ½ÃÇàµÇ¾úÀ¸¸ç ´ëºÎºÐÀÇ ¿¬±¸¿¡¼­ ¸¶¾à¼º ÁøÅëÁ¦·Î ÀÎÇØ ºÎ½Å±â´ÉÀÇ ÀúÇϰ¡ ³ªÅ¸³µÀ½À» º¸¿©ÁÖ¾ú´Ù. ±×·¯³ª ¾ÆÁ÷ ¾ÏȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ ¸¶¾à¼º ÁøÅëÁ¦·Î ÀÎÇÑ ºÎ½Å±â´ÉÀÇ ÀúÇÏ¿¡ ´ëÇÑ ¿¬±¸ °á°ú´Â µå¹°´Ù. ¸¶¾à¼º ÁøÅëÁ¦·Î ÅëÁõ Á¶ÀýÀ» ¹Þ°í ÀÖ´Â ¿ÏÈ­ÀǷẴµ¿¿¡ ÀÔ¿øÇÑ ¸»±â¾ÏȯÀÚµéÀÇ ºÎ½Å±â´ÉÀ» ÃøÁ¤ÇÔÀ¸·Î½á ¸¶¾à¼º ÁøÅëÁ¦ÀÇ Á¾·ù, »ç¿ë±â°£ ¹× ¿ë·®°ú ºÎ½Å±â´ÉÀÇ °ü°è¸¦ ÆÄ¾ÇÇϰí ÀÌ¿¡ µû¸¥ ´ëÁõÄ¡·á ¹× È£¸£¸ó º¸Ãæ ¿ä¹ýÀº ȯÀÚµéÀÇ ¿¹ÈÄ ¹× »îÀÇ Áú Çâ»ó¿¡ µµ¿òÀ» ÁÙ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµÈ´Ù.
The major symptoms of terminally ill cancer patients are fatigue, loss of energy, feeling of helplessness, poor appetite and pain as well as general weakness, which are very similar to symptoms of adrenal insufficiency. Adrenal insufficiency-induced symptoms widely vary from mild symptoms to life-threatening conditions and may be resulted from variable medical causes. For terminally ill cancer patients who are hospitalized for palliative care, opioid agents are prescribed to control moderate to severe pain. The use of acute or chronic opioid agents is believed to negatively affect adrenal gland function. In most studies of opioid effects (preclinical/clinical with animal subjects or and patients suffering non-malignant pain, adrenal insufficiency and hormonal abnormalities were observed as side effects. However, opioid-induced adrenal insufficiency has been rarely reported in studies with patients with malignant cancer pain. Relationship between the type, treatment period, dosage of opioid agents and hormonal abnormalities can be examined by measuring the functional level of the adrenal glands. We hope to improve patient¡¯s quality of life by indicating hormone substitution to treat symptoms of adrenal insufficiency.

Ű¿öµå

ºÎ½Å±â´ÉºÎÀü, ¸¶¾à¼º ÁøÅëÁ¦, µðÇÏÀ̵å·Î¿¡ÇǾȵå·Î½ºÅ×·Ð, ÇÏÀ̵å·ÎÄÚÆ¼¼Õ
Adrenal insufficiency, Opioid analgesics, Dehydroepiandrosterone, Hydrocortisone
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Ű¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆÇ³âµµ(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå